ive Attenuated Rift Valley Fever Vaccine for Single Shot Administration (LARISSA)
Phase 1
- Conditions
- Rift Valley fever (RVF) infectionTherapeutic area: Diseases [C] - Virus Diseases [C02]
- Registration Number
- CTIS2022-501460-17-00
- Lead Sponsor
- Cr2o B.V.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- All
- Target Recruitment
- 75
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method